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Summary 59 
 60 
In the last five years, childhood tuberculosis (TB) has received increasing attention from 61 
international organisations, national TB programmes, and academics. For the first time, a 62 
number of different groups are developing techniques to estimate the burden of childhood 63 
TB. We review the challenges in diagnosing TB in children and the reasons cases in children 64 
can go unreported. We discuss the importance of an accurate understanding of burden for 65 
identifying problems in programme delivery, targeting interventions, monitoring trends, 66 
setting targets, allocating resources appropriately and providing strong advocacy. We briefly 67 
review the estimates produced by new analytical methods, outline the reasons for recent 68 
improvements in our understanding, and potential future directions. We conclude that 69 
while innovation, collaboration and better data have improved our understanding of 70 
childhood TB burden, it remains substantially incomplete.  71 
Introduction 72 
 73 
Childhood tuberculosis (TB) has been neglected for many years by the international 74 
community. There has been a lack of interest from international agencies, national TB 75 
programmes (NTPs), clinicians, academics, advocates and funders. In March 2011 a meeting 76 
was convened in Stockholm to discuss childhood TB.
1
 Over 110 participants attended 77 
representing a wide variety of stakeholders and the group discussed the challenges in 78 
addressing childhood TB, as well as identifying key advocacy areas for development. The 79 
meetiŶŐƌĞƐƵůƚĞĚŝŶĂ ‘ĂůůƚŽĐƚŝŽŶĨŽƌŚŝůĚŚŽŽĚd ?, which was endorsed by over 800 80 
individuals and organisations in nearly 100 countries. Since then, interest in childhood TB 81 
has increased, resulting in greater visibility, funding, research and advocacy. In 2012 the 82 
World Health Organization (WHO) published their first estimate of the number of children 83 
that develop TB each year;
2
 estimates are now reported annually, and the methodology 84 
used continues to evolve. In 2013, the WHO, in collaboration with other organisations such 85 
as The International Union Against Tuberculosis and Lung Disease (The Union) and United 86 
Nations Children's Fund (UNICEF), published the International Roadmap for Childhood 87 
Tuberculosis.
3
 As a critical first step in moving forward, the Roadmap highlighted the need 88 
ƚŽ “ŬŶŽǁǇŽƵƌĞƉŝĚĞŵŝĐ ? ?Also in 2013, the WHO and the Global Alliance for TB Drug 89 
Development (TB Alliance) organised a consultation to define and prioritise data gaps and 90 
analytical methods relevant to our understanding of childhood TB burden. This consultation 91 
shaped collaborations between relevant stakeholders and spurred the development of 92 
complementary analytical methods.
4
  93 
 94 
This article discusses some of the challenges in estimating the burden of childhood TB, 95 
describes the importance of robust estimates, considers the varied techniques used to 96 
arrive at estimates, and discusses future directions. It uses the estimation of TB incidence in 97 
children as a case study for how a successful collaboration between institutions and 98 
academic groups can catalyse improvement in analytical methods. Within the article 99 
children are considered as those aged less than fifteen years. 100 
 101 
Challenges to estimating the burden of childhood tuberculosis  102 
 103 
In many settings, and particularly where TB is common, very few TB cases in children are 104 
bacteriologically confirmed for a number of reasons: first, it can be challenging to obtain 105 
samples from young children for laboratory diagnosis; second the paucibacillary nature of 106 
disease in many children means that the yield from bacteriological techniques such as smear 107 
microscopy is often low;
5,6
 and finally, and laboratory diagnosis with culture or Xpert 108 
MTB/RIF is usually not available in facilities where children present. Diagnosis therefore 109 
often relies upon clinical assessment supported by diagnostic tools (e.g. chest X-ray) that 110 
have significant limitations in specificity and sensitivity.
7,8
 A large number of children with 111 
TB are therefore likely to remain undiagnosed each year. In addition to the diagnostic 112 
uncertainties, a major challenge for estimating burden is under-reporting. Until recently, 113 
NTPs of most TB endemic countries were required to only report sputum smear-positive 114 
cases and would report children in a broad age category of 0-14 years. This led to the 115 
perception (or misperception) that the burden in children was low. NTPs are now requested 116 
to report all TB cases and by two age bands for children (0-4 years, 5-14 years). However, 117 
the NTP can only report data for those children that are registered with the NTP at the time 118 
of diagnosis. Unfortunately, a large but unknown number of children are treated for TB but 119 
are not registered with the NTP.
9,10
 120 
 121 
The challenges of confirming diagnosis are greatest in infants and young children (<5 years 122 
age); importantly, this age group also has an increased risk of severe disease and TB-related 123 
mortality.  Although uncomplicated lymph node disease is common in children, a substantial 124 
proportion also develop severe forms of disseminated TB, such as miliary TB or TB 125 
meningitis,
11
 that are associated with significant morbidity and mortality,
12,13
 or present 126 
with concomitant severe pneumonia or malnutrition.
14
 Finally, from a public health 127 
viewpoint, it is important to recognise that children can transmit TB to contacts, especially 128 
older children and adolescents who often develop adult-type or cavitary TB that is highly 129 
infectious.
15-19
  130 
 131 
What is meant by disease burden? 132 
 133 
The term disease burden describes the number, and the associated rate, of individuals in a 134 
community with a particular condition and its consequences for morbidity, disability and 135 
mortality.  Traditionally, in the field of TB, incidence, prevalence and mortality have all been 136 
estimated and reported as measures of disease burden. The three measures are related and 137 
although each require a different estimation approach, comparison between the three 138 
allows verification of internal consistency. The three measures tell us different things about 139 
the epidemic. Incidence refers to the number of individuals who develop TB each year; 140 
prevalence the number at a given time point who have TB; and mortality the number who 141 
die each year with TB thought to be the primary cause. To take into account the size of the 142 
population in reference, and to compare across communities and with other diseases, the 143 
corresponding incidence, prevalence and mortality rates are also calculated. 144 
 145 
 146 
 147 
Importance of estimates 148 
 149 
Accurate and reliable childhood TB incidence estimates, when compared with the number 150 
of reported and treated cases from national surveillance systems, quantify the degree to 151 
which children with TB are not being found, diagnosed or treated. This may help to identify 152 
weak links in the cascade from symptoms to presentation to diagnosis to treatment to 153 
official notification (Figure 1). Investigation of these links may then suggest actions to 154 
improve case detection and reporting. Discrepancies in notifications or quality of detection 155 
and reporting among epidemiologically similar settings may alert programmes to existing 156 
problems and provide new insights into how these problems may be resolved. Specific 157 
programmatic indices may also give a crude indication of overall childhood TB management 158 
(Table 1).  159 
 160 
As children can only have been infected in the few years since birth, and as most 161 
progression is within 12 months,
20
 TB in children represents recent transmission. Childhood 162 
TB therefore also provides insight into which strains of M. tuberculosis are currently 163 
circulating in a community (including drug-resistant strains). TB incidence in children reflects 164 
local transmission rates, and therefore is a potential indicator for TB control more 165 
generally.
21
 Accurate baseline numbers and trends over time allow appropriate national and 166 
global targets to be set, and assessment of whether they are met.  167 
 168 
Robust estimates help inform the service planning, resource allocation, and the targeting of 169 
interventions to where they are needed most. In addition they permit an appropriate 170 
assessment of the potential market for new diagnostics, vaccines and drugs. Industry, 171 
academic funding organisations, development agencies, non-governmental organisations 172 
and NTPs, all want to make rational investment decisions, and burden quantification is 173 
therefore an essential component in engaging with them. Further, for purposes of advocacy, 174 
knowing the burden of disease is a tool to raise the profile of these vulnerable children and 175 
motivate better diagnostics, treatments, funding, rights, support or recognition. The 176 
importance of accurate estimates is summarised in Table 2. 177 
 178 
Methodology for estimation of childhood tuberculosis incidence 179 
 180 
Until recently, the WHO did not publish separate childhood TB estimates, partly due to 181 
difficulties in interpreting notification data for children, and partly because many countries 182 
did not then disaggregate notifications by age. Over the last ten years the number of 183 
countries reporting disaggregated data has sharply increased (Figure 2). The WHO published 184 
its first official estimate in 2012.
2
 As a starting point, they followed a two-step procedure 185 
(Figure 3): first estimating paediatric notifications for countries that did not disaggregate by 186 
age, and secondly estimating the underlying incidence through dividing notifications by a 187 
case detection ratio (CDR). Acknowledged limitations included the assumption that the 188 
paediatric CDR was the same as the CDR for adults (66%, range 64-69%); the assumption of 189 
no misclassification of TB in the paediatric notifications; and the assumption that the 190 
proportion of TB burden among children was the same whether countries disaggregated 191 
notifications by age or not. Commentators were concerned that the assumption of an equal 192 
CDR for adults and children was at odds with observational evidence of under-reporting and 193 
under-diagnosis,
9,10
 and would lead to an underestimated paediatric incidence estimate. 194 
 195 
More recently, other groups have used complementary methods to estimate the TB burden 196 
in children. Jenkins and colleagues
22
 followed a different procedure based on using the 197 
expected proportion of smear-positive cases in each age group
23
 to obtain an adjusted 198 
proportion of TB incidence among children (Figure 4). A regression of the proportion of TB in 199 
children against total incidence
24
 was then used to predict this proportion in countries not 200 
disaggregating notifications by age. Finally, these country-level proportions were multiplied 201 
by the WHO total country TB estimates and aggregated to predict that 999,792 (95% 202 
confidence interval: 937,877 W1,055,414) children developed TB in 2010. Limitations of this 203 
approach include the shortcomings of notification data and the challenges in estimating TB 204 
incidence,
25
 which represent sources of error and uncertainty that are not captured in the 205 
confidence interval of this paediatric TB estimate. Furthermore, the assumption that the 206 
age-specific proportions of TB cases that are smear-positive from previous studies
23
 are 207 
representative of the present day proportions across all countries requires further review; 208 
such an effort is currently in progress.
26
 If countries replace smear microscopy with other 209 
diagnostic tools, this estimation method may need to be modified to account for the age-210 
specific operation characteristics of those tools 211 
 212 
Dodd and colleagues used a mathematical modelling approach to produce an estimate 213 
independent of paediatric notifications,
27
 initially focussing on the twenty-two high-burden 214 
countries in 2010. Demographic data and WHO TB prevalence estimates were used to 215 
predict the incidence of TB infection in children. An age-dependent model of progression to 216 
extra-pulmonary TB and pulmonary TB was then used to estimate the incidence of disease, 217 
taking into account country-level BCG vaccination coverage and HIV prevalence (Figure 5). 218 
This resulted in a global estimate for childhood TB incidence for 2013 of median 827,000 219 
cases (IQR: 549,000-1,245,000). Limitations include shortcomings in adult TB prevalence 220 
estimates, uncertainty around the impact of BCG and HIV, and the applicability of data from 221 
the literature to present-day risk of disease progression. 222 
 223 
The Institute of Health Metrics and Evaluation (IHME) also produce estimates for childhood 224 
TB,
28
 as part of the Global Burden of Disease (GBD) study
29,30
 with mortality, prevalence and 225 
incidence estimated simultaneously. Mortality estimates rely on vital registration and verbal 226 
autopsy data, tools with associated challenges and limitations
31
 Estimates of prevalence and 227 
incidence of childhood TB are made using data from prevalence surveys, notification data 228 
and the addition of the GBD mortality estimates in a Bayesian meta-regression tool, 229 
DisMod-MR 2.0.  The differential equations built into DisMod-MR 2.0 force consistency in 230 
the estimates of incidence, prevalence and TB mortality rates. In children 0-14 years old, 231 
187,944 (181,637 to 193,832) incident cases of TB were estimated globally. With few 232 
observed prevalence data points, these estimates rely heavily on the notification data with 233 
the above mentioned limitations of under-diagnosis of TB in childhood, the application of a 234 
coarse case detection rate by country at all ages and the lack of age, sex and type of TB 235 
detail in most notification data. 236 
 237 
In 2014 WHO used an ensemble approach to estimate paediatric TB incidence,
32
 producing a 238 
weighted average of their notification-based estimate and the estimate derived from the 239 
mathematical model by Dodd et al.
27
 The resulting estimate of global TB incidence among 240 
children in 2013 was 550,000 (range 470,000-640,000), equivalent to about 6% of the total 241 
number of 9.0 million incident cases. 242 
 243 
Drug-resistant tuberculosis estimation  244 
 245 
Jenkins and colleagues also estimated the burden of multidrug-resistant (MDR) TB in 246 
children. Their systematic review evaluated a linear association between the proportion of 247 
MDR-TB in children and treatment naïve adults. Combined with their estimates of childhood 248 
TB incidence, this implied 31,948 (IQR: 25,594-38,663) children developed MDR-TB in 249 
2010.
22
 In a subsequent study, Yuen and colleagues undertook a systematic review of the 250 
proportion of paediatric cases that were isoniazid-resistant in 2010.
33
 The group estimated 251 
that 12.1% (95%CI: 9.8-14.8%) of all children with TB have isoniazid-resistant disease, 252 
resulting in 120,872 (95%CI: 96,628-149,059) incident cases in 2010.
34
  253 
 254 
The changing landscape of burden estimation 255 
 256 
Estimates for childhood TB burden are improving for several reasons. First, a number of 257 
different, complementary approaches have been taken. The existence of these disparate 258 
methods, and the collaboration between the groups that have developed them, provide an 259 
opportunity to scrutinize and understand differences in estimates in order to refine and 260 
improve methods. Second, increased training, education and policy changes mean more 261 
paediatric cases are being identified, registered and reported; non-bacteriologically 262 
confirmed cases are increasingly being entered into registers. Third, the number of 263 
countries that disaggregate data by age has increased. Fourth, many countries have 264 
developed paediatric TB committees or sub-groups within the NTP and age-specific 265 
indicators have been promoted in a number of settings. Fifth, inventory (or capture-266 
recapture) studies to determine the discrepancy between treated cases and reported cases 267 
are being conducted in several countries, and will give valuable data in countries with a 268 
large private heath-provider sector. Sixth, electronic reporting of data is more widespread, 269 
improving accuracy and completeness. Seventh, more surveys, better surveillance and an 270 
increased number of academic studies are being conducted into childhood TB to improve 271 
primary data sources. Finally, children who died of TB in hospital were frequently not 272 
registered with NTPs; this is improving. 273 
 274 
Scientific developments in diagnostics may increase the number of children who are 275 
diagnosed, treated and reported to NTPs. Recently, Xpert MTB/RIF was evaluated in 276 
children and was found to be more sensitive than sputum smear microscopy.
6
 An RNA gene 277 
ĞǆƉƌĞƐƐŝŽŶƐƚƵĚǇŚĂƐŝĚĞŶƚŝĨŝĞĚĂƵŶŝƋƵĞ ‘ƐŝŐŶĂƚƵƌĞ ?ŝŶ ƚŚĞŝŵŵƵŶĞƌĞƐƉŽŶƐĞƚŚĂƚ ?ŝĨ278 
converted into a point-of-care test, could improve our ability to diagnose TB in children.
35
  279 
 280 
In 2013, TB Alliance was awarded USD16.7 million from UNITAID to develop child-friendly 281 
formulations for TB drugs for children.
36
 Part of this project is to quantify the potential 282 
market for first- and second-line TB drugs for children, in order to engage with 283 
pharmaceutical companies. This funding, as well as providing estimates of market, has 284 
funded additional work into estimating and describing the burden of TB in children.  285 
 286 
NTP reviews have been one of the motivating factors used to drive through change in 287 
national TB policy to identify, treat and report childhood TB. In many countries, funding 288 
from the Global Fund is contingent on demonstrating responses to suggestions made in NTP 289 
reviews. Increasingly there are paediatric TB specialists on the team that conducts these 290 
reviews and evaluate paediatric-specific indicators. The specialists then provide suggestions 291 
and targets specifically for childhood TB.  292 
 293 
Future Perspectives 294 
 295 
Increased use of modelling and better data on which to build models will improve the 296 
accuracy of new estimates. It is also possible to use modelling to identify which data inputs  297 
contribute most to the uncertainty in the overall estimates. Such analysis can consequently 298 
hep prioritize areas of primary data collection for improving the accuracy of estimates. 299 
Comparison and synthesis of modelling methodology will also help. Assessing these 300 
estimates over time also allows an appreciation of changing trends. Ideally, further 301 
disaggregation of reported data would take place so that children are reported in five-year 302 
age-bands (0-4 years, 5-9 years, and 10-14 years). In addition, the inclusion of children into 303 
appropriately designed prevalence surveys would allow a better grasp of primary data, and 304 
lead to better-validated models. Children have not been included in prevalence surveys due 305 
to a number of logistical, financial and ethical challenges.
37,38
 However, it may be possible to 306 
include children, using a modified approach, in certain sentinel sites. Many investigators, 307 
policy-makers and public health experts, including authors of this article, are currently 308 
working on how this could be done in practice, with the aim of producing clear protocols 309 
and algorithms. As we move from the Millennium Development Goals to the Sustainable 310 
Development goals, there is the opportunity to critically review how prevalence surveys are 311 
conducted, including how to include children, as well as how to incorporate newer 312 
diagnostic methods. As estimates become more accurate and modelling becomes more 313 
sophisticated, it will be possible to model the impact of interventions on the burden of 314 
childhood TB. Sound estimates of both the cost and cost-effectiveness of these 315 
interventions will provide information and powerful motivation to policy-makers and 316 
politicians.  317 
 318 
Conclusion 319 
 320 
Collaboration among the WHO, the Union, the Child Health Epidemiology Reference Group 321 
(CHERG), IHME, TB Alliance and different academic groups has greatly improved our 322 
understanding of the burden of childhood TB in the last couple of years. New and innovative 323 
methods are being used to estimate burden and improvements in reporting are being seen. 324 
There has been increased investment and significant progresses in scientific research. 325 
However, we are still some way from a complete understanding of which children get TB 326 
and how best to find them. 327 
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 Table 1: Programmatic indicators that may give an indication of how well childhood tuberculosis is being diagnosed and reported 
Indicator Approximate expected value
1
 
Likely interpretation if: 
Too high Too low 
Proportion of overall burden 
found in children 
5%-20%, increasing with overall 
TB incidence 
Over-diagnosis of childhood TB Under-diagnosis of childhood TB 
Proportion of treated paediatric 
cases with a confirmed diagnosis 
20-30%, increasing with age and 
resources 
Not enough children treated on clinical 
grounds 
Not enough effort made to confirm 
the diagnosis  
Proportion of paediatric cases 
that are sputum smear-positive
2
 
10% in 0-14 age group as a whole 
Not enough children treated on clinical 
grounds 
Not enough effort made to confirm 
the diagnosis  
Proportion paediatric cases that 
are under-5 years 
Slightly over 50%  
Too many young children being treated 
clinically 
KŶůǇŽůĚĞƌĐŚŝůĚƌĞŶǁŝƚŚ ‘ĐůĂƐƐŝĐ ?
symptoms being treated or only 
children with confirmed disease 
treated 
Proportion of paediatric cases 
that are EPTB 
10% in 0-14 age group as a whole; 
25% in 0-4 age group 
Children with various clinical 
characteristics (such as cervical 
lymphadenopathy) being diagnosed with 
TB when many do not have TB 
Only confirmed cases (which are 
frequently PTB) classified as TB 
 
TB: tuberculosis; EPTB: extra-pulmonary tuberculosis 
1
These expected values provide a rule-of-thumb or guide only. Enormous variability in these parameters has been described in studies across different settings 
2
Since 2013, cases are now reported to WHO according to whether bacteriologically confirmed, which includes confirmation by smear microscopy, culture and Xpert MTB/RIF 
  
Table 2: Reasons for the importance of more accurate estimates of the burden of childhood tuberculosis 
Needs for better estimates 
 
Rationale for better estimates 
Political engagement and political will 
Accurate data of the burden of tuberculosis in children are required to engage the leadership and 
support of the tuberculosis control sector, the child health sector, government health ministries, 
advocacy groups and the wider community. 
Inform situational analysis and identify gaps 
/ƚŝƐĐƌŝƚŝĐĂůƚŽ “ŬŶŽǁǇŽƵƌĞƉŝĚĞŵŝĐ ?ŝŶŽƌĚĞƌƚŽŝĚĞŶƚŝĨǇĐƵƌƌĞŶƚŐĂƉƐĂŶĚĐŚĂůůĞŶŐĞƐĂƐǁĞůůĂƐ
priorities for implementation to address child tuberculosis. 
Child TB is an indicator for surveillance of recent 
transmission   
Accurate data of tuberculosis in young children monitored over time could be an important 
tuberculosis control indicator as a sensitive indicator of recent transmission and an early indicator of 
ƚƌĂŶƐŵŝƐƐŝŽŶ “ŚŽƚ-ƐƉŽƚƐ ? ?
Resource allocation for health systems and NTP 
The numbers of children with drug-sensitive and drug-resistant tuberculosis will inform health service 
and human resource requirements to ensure effective programmatic management.  
Procurement needs of diagnostics and therapeutics 
The numbers of children with drug-sensitive and drug-resistant tuberculosis will inform the needs and 
sufficient procurement of diagnostic tools and anti-tuberculosis medication, including medication 
suitable for young children.  
Engage the Maternal and Child Health sector  
Data that show the importance of tuberculosis in the context of child morbidity and mortality are 
required to engage the leadership and support of the Maternal and Child Health sector and 
government, especially as most countries include child health as a major national priority. 
Advocacy and engagement of civil society 
Accurate data of the burden of tuberculosis with direct and indirect consequences on child health are 
extremely valuable for advocacy groups, national champions and civil society to highlight the need for 
action. 
Monitoring and evaluation tool  
Accurate baseline data are required to monitor and evaluate implementation of activities aiming to 
improve the detection, prevention and management of child tuberculosis.  
Identification of needs and improves quality of 
research    
Accurate data would greatly strengthen the many opportunities for operational research in children 
as well as the quality of clinical trials that evaluate novel diagnostics or therapeutic regimens.  
Potential for investment in novel diagnostics and 
therapeutics  
dŚĞƉŽƚĞŶƚŝĂů “ƐŝǌĞŽĨƚŚĞŵĂƌŬĞƚ ?ŝƐŽŶĞŝŵƉŽƌƚĂŶƚĨĂĐƚŽƌƚŚĂƚŝŶĨŽƌŵƐŝŶǀĞƐƚŵĞŶƚŝŶƌĞƐĞĂƌĐŚĂŶĚ
development of novel diagnostics and therapeutics.  
 
TB: tuberculosis; NTP: National TB Programme 
  
Figure 1: The cascade from symptoms to reporting in children with tuberculosis 
 
 
 
TB: tuberculosis; WHO: World Health Organization 
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TB: tuberculosis; ARI: annual risk of infection; HIV: human immunodeficiency virus; BCG: Bacillus Calmette WGuérin; EPTB: extra-pulmonary tuberculosis; PTB: pulmonary tuberculosis 
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